Clinical trials: Rosacea
Wrinkle, Rosacea
Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment
Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array (MLA) Attachment
- Conditions
- Wrinkle, Rosacea, Scarring
- Trial name
- NCT03424304
- Testing
- Excel V™ Laser With Green Genesis
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Erythema, Rosacea
Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with…
- Trial name
- NCT02132117
- Testing
- Oxymetazoline HCL Cream 1.0%, Vehicle to Oxymetazoline HCL Cream
- Where
- United States
- Volunteers
- 445 people
- Sponsor
- Allergan
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03564119
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Rosacea
ORCA - Oracea® for Rosacea: A Community-based Assessment
The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
- Trial name
- NCT00892281
- Testing
- doxycycline (Oracea®) 40 mg modified release as monotherapy, doxycycline (Oracea®) 40 mg modified release as add-on therapy
- Where
- United States
- Volunteers
- 1,421 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
- Trial name
- NCT01872715
- Testing
- Oracea
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Erythematotelangiectatic Rosacea
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single…
- Trial name
- NCT00989014
- Testing
- CD07805/47
- Where
- 5 sites in United States
- Volunteers
- 122 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03448939
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Rosacea
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.
- Trial name
- NCT01426269
- Testing
- Doxycycline, Metronidazole
- Where
- 11 sites in United States
- Volunteers
- 235 people
- Sponsor
- Galderma R&D
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.
Rosacea
Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved rosacea drug product in the treatment of facial erythema of rosacea.
- Trial name
- NCT02385240
- Testing
- Brimonidine Topical Gel, 0.33 percent (Perrigo), Brimonidine Topical Gel, 0.33 percent (Reference)
- Volunteers
- 552 people
- Sponsor
- Padagis LLC
Rosacea
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.
- Trial name
- MUSE (NCT02637232)
- Testing
- Mirvaso® / Onreltea TM
- Where
- Canada
- Volunteers
- 301 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
- Trial name
- NCT03564145
- Testing
- S5G4T-1
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Erythema, Rosacea
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
- Trial name
- NCT02131636
- Testing
- AGN-199201, Vehicle to AGN-199201
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Allergan
Rosacea
Oracea Soolantra Association in Participants With Severe Rosacea
The main objective of this study is to evaluate the efficacy of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the…
- Trial name
- ANSWER (NCT03075891)
- Testing
- Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 273 people
- Sponsor
- Galderma R&D
Blepharitis, Meibomianitis
Treatment of Patients With Blepharitis and Facial Rosacea
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
- Conditions
- Blepharitis, Meibomianitis, Dry Eye
- Trial name
- NCT00560703
- Testing
- COL-101 (doxycycline, USP) capsules
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Galderma R&D
Erythematous Rosacea
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
- Trial name
- NCT00697541
- Testing
- 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Rosacea
A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
The purpose of this exploratory study is to assess the efficacy, safety and tolerability of DFD-04 Ointment for topical treatment of rosacea over 12 weeks of treatment.
- Trial name
- NCT02828241
- Testing
- DFD-04 Ointment
- Where
- 8 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Erythema, Rosacea
Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
This is a study to evaluate inter- and intra-rater reliability of the Clinician Erythema Assessment Scale. There is no treatment (intervention) associated with this study.
- Trial name
- NCT01636765
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Allergan